Comparative Analysis of the Results of Orthotopic Liver Transplantation in Patients With and Without Portal Vein Thrombosis

2005 ◽  
Vol 37 (9) ◽  
pp. 3899-3903 ◽  
Author(s):  
F.A. Gimeno ◽  
J. Calvo ◽  
C. Loinaz ◽  
J.C. Meneu ◽  
B. Pérez ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Comparative Analysis ◽  
Portal Vein ◽  
Portal Vein Thrombosis ◽  
Orthotopic Liver Transplantation ◽  
Vein Thrombosis

Dabigatran Reversal With Idarucizumab in 2 Patients With Portal Vein Thrombosis Undergoing Orthotopic Liver Transplantation

2021 ◽  
pp. 108925322098218
Author(s):  
Cynthia Williams ◽  
Erin Stewart ◽  
Kendra D. Conzen ◽  
Scott Wolf ◽  
Timothy T. Tran
Keyword(s):  
Liver Transplantation ◽  
Portal Vein ◽  
Portal Vein Thrombosis ◽  
Orthotopic Liver Transplantation ◽  
Oral Anticoagulants ◽  
Direct Oral Anticoagulants ◽  
Case Series ◽  
Reversal Agent ◽  
Vein Thrombosis ◽  
Cirrhotic Patients

There are limited data to guide the use of anticoagulation in cirrhotic patients prior to liver transplantation especially when using direct oral anticoagulants. In this article, we present 2 cases. The first is a 42-year-old male with cirrhosis complicated by portal vein thrombosis (PVT) treated with dabigatran who underwent orthotopic liver transplantation without complication. The second case is a 65-year-old man with alcoholic cirrhosis complicated by PVT treated with dabigatran who underwent orthotopic liver transplantation and required reoperation for surgical bleeding. Both patients were treated with dabigatran’s reversal agent idarucizumab prior to incision. In this case series, we discuss the treatment of cirrhotic patients with various anticoagulants, considerations for anticoagulant selection and reversal prior to liver transplant, and questions for future investigation.

scholarly journals Protein C in a patient with portal vein thrombosis in liver transplantation

2021 ◽  
Vol 13 (2) ◽  
pp. 151-157
Author(s):  
S. V. Zhuravel ◽  
V. E. Aleksandrova ◽  
N. K. Kuznetsova ◽  
M. S. Novruzbekov ◽  
L. V. Donova
Keyword(s):  
Liver Transplantation ◽  
High Risk ◽  
Plasma Level ◽  
Portal Vein ◽  
Portal Vein Thrombosis ◽  
Orthotopic Liver Transplantation ◽  
Protein C ◽  
Post Transplant ◽  
Vein Thrombosis ◽  
Hemostasis System

Background. The problem of thromboses, including those associated with impaired hemostasis system, is relevant in orthotopic liver transplantation.Aim. To present the experience of intraoperative use of protein C during orthotopic liver transplantation in a patient with a high risk of recurrent portal vein thrombosis.Results. During orthotopic liver transplantation in a patient with a high risk of recurrent portal vein thrombosis, the intraoperative administration of the protein C preparation at a dosage of 500 IU contributed to the increase in plasma level of protein C by 48%. In the post-transplant period, recurrent portal vein thrombosis was not observed. Conclusion. Intraoperative administration of protein C in combination with basic therapy for orthotopic liver transplantation helps to prevent recurrent portal vein thrombosis.

Sign in / Sign up

Export Citation Format

Share Document